sodium tetraiodotetrachlorofluorescein
Small moleculeexperimentalImaging agent
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2015 (NCT02322086)
Timeline
2010s
- Jan 1, 2015
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
Loading structure…
SMILES
O=C(O)c1c(Cl)c(Cl)c(Cl)c(Cl)c1-c1c2cc(I)c(=O)c(I)c-2oc2c(I)c(O)c(I)cc12- Mol. weight
- 973.67 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Discontinued
Oral
No
Parenteral
Yes
Topical
No
Sources
- ChEMBLCHEMBL1208422 ↗
- ChEMBLCHEMBL1160160 ↗
Also known as
- 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodofluorescein
- rose bengal
- rose bengal
- rose bengal
- rose bengal
- rose bengal
- rose bengal
- rose bengal sodium
- rose bengal sodium
- rose bengal sodium
- sodium tetraiodotetrachlorofluorescein
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02322086 | Phase 2 | Jan 1, 2015 | Provectus Biopharmaceuticals, Inc. |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Provectus Biopharmaceuticals, Inc. | For profit | 1 | 1 | 1 | 2015 |
1 organizations
Page 1 / 1